TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26528775

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg + placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remifentanil (highest TCI level)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pregabalin + Remifentanil (highest TCI level)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pregabalin + Remifentanil
Number of subjects: 12
Study: 24656590

Group type: EXPERIMENTAL
Intervention: Intratendinous injection of platelet-rich plasma (PRP) under ultrasound (US) guidance
Number of subjects: 408
Study: 22173883

Group type: EXPERIMENTAL
Intervention: Blue Dog software program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Fire safety software program
Number of subjects: 76
Study: 20102140

Group type: EXPERIMENTAL
Intervention: Distance education intervention for rural nurses regarding mammography screening.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 17494667

Group type: EXPERIMENTAL
Intervention: Proton MR spectroscopy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MRI volumetry
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 15789016

Group type: EXPERIMENTAL
Intervention: Docking reconstructions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EndoButton reconstructions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interference screw reconstructions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Figure‐eight reconstructions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intact ligaments
Number of subjects: 20
Study: 11870792

Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser treatment (1-5 sessions)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser treatment (5 sessions)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser treatment
Number of subjects: 29
Study: 10094216

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg plus Fluticasone propionate 88 microg
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg plus Fluticasone propionate 220 microg
Number of subjects: 136

Group type: COMPARATOR
Intervention: Fluticasone propionate 88 microg
Number of subjects: 136

Group type: COMPARATOR
Intervention: Fluticasone propionate 220 microg
Number of subjects: 136

Group type: COMPARATOR
Intervention: Salmeterol 42 microg
Number of subjects: 136
Study: 7595744

Group type: EXPERIMENTAL
Intervention: CHVmP-VB
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ProMACE-MOPP
Number of subjects: 64

Group type: COMPARATOR
Intervention: IFN
Number of subjects: 64

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 64
Study: 2134116

Group type: EXPERIMENTAL
Intervention: Oxiracetam (800 mg t.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30368018

Group type: EXPERIMENTAL
Intervention: Fulranumab (9 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Fulranumab
Number of subjects: 98
Study: 28578900

Group type: EXPERIMENTAL
Intervention: Healthy Home Offerings via the Mealtime Environment Plus program (intervention)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 27960007

Group type: EXPERIMENTAL
Intervention: Literate language intervention (4 instructional units on prepositions, conjunctions, adverbs, and negations, delivered by paraprofessionals in small groups, 20-min lessons 4 times a week for 12 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 82
Study: 24804272

Group type: EXPERIMENTAL
Intervention: Liberal transfusion protocol (transfusion if hemoglobin dropped below 9.9 g dL(-1))
Number of subjects: 58

Group type: COMPARATOR
Intervention: Restrictive transfusion protocol (transfusion if hemoglobin dropped below 7.7 g dL(-1))
Number of subjects: 58
Study: 21910025

Group type: EXPERIMENTAL
Intervention: Multifaceted efficacy intervention (MEI)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 140
Study: 30049303

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Coadministration of Mirogabalin 15 mg with Metformin 850 mg
Number of subjects: 21
Study: 18043099

Group type: EXPERIMENTAL
Intervention: Unilateral neck exploration
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bilateral neck exploration
Number of subjects: 91
Study: 16198888

Group type: EXPERIMENTAL
Intervention: Color Doppler tissue imaging-derived parameters of peak systolic velocity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color Doppler tissue imaging-derived parameters of myocardial acceleration during isovolumic contraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interobserver reliability for peak systolic velocity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for peak systolic velocity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interobserver reliability for myocardial acceleration during isovolumic contraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for myocardial acceleration during isovolumic contraction
Number of subjects: 0
Study: 11995260

Group type: EXPERIMENTAL
Intervention: Montelukast (5-10 mg once daily for three months)
Number of subjects: 31
Study: 10784382

Group type: EXPERIMENTAL
Intervention: Chronic supplementation with 15 g of arginine aspartate daily for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Carbohydrate‐based placebo
Number of subjects: 14
Study: 7568859

Group type: EXPERIMENTAL
Intervention: Uniphasic injection of 38 g of iodine
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Uniphasic injection of 26 g of iodine
Number of subjects: 487

Group type: COMPARATOR
Intervention: Biphasic injection
Number of subjects: 487
Study: 2122131

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with mitomycin C (MMC), tegafur, and PSK
Number of subjects: 255

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 255
Study: 7427705

Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg four times daily for seven days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg four times daily for seven days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both regimens (250 mg and 500 mg)
Number of subjects: 200
Study: 31647886

Group type: EXPERIMENTAL
Intervention: Supplemental whey protein (PRO) 25 g, 3×/day for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA) 25 g, 3×/day for 12 weeks
Number of subjects: 21
Study: 30069754

Group type: EXPERIMENTAL
Intervention: Mental health conditions (e.g., schizophrenia, obsessive compulsive disorder)
Number of subjects: 13000

Group type: COMPARATOR
Intervention: Physical health conditions
Number of subjects: 13000
Study: 26963724

Group type: EXPERIMENTAL
Intervention: Laparoscopy (LA group)
Number of subjects: 180
Study: 25815419

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: All subtype groups
Number of subjects: 1008
Study: 22916715

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Number of subjects: 197

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine
Number of subjects: 197
Study: 20022408

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 19258384

Group type: EXPERIMENTAL
Intervention: LF (Balance, Fresenius)
Number of subjects: 91

Group type: COMPARATOR
Intervention: CF (CAPD/DPCA, Fresenius)
Number of subjects: 91
Study: 17609405

Group type: EXPERIMENTAL
Intervention: Proinsulin levels >5 pmol/l with blood glucose levels <2.5 mmol/l during a 72 h fast test
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C-peptide levels >0.2 nmol/l
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Proinsulin levels >22 pmol/l
Number of subjects: 100

Group type: COMPARATOR
Intervention: Proinsulin levels <22 pmol/l
Number of subjects: 100
Study: 15308521

Group type: EXPERIMENTAL
Intervention: Weekly oral azithromycin for 13 weeks (1 g single dose for Chlamydia infection)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 11355895

Group type: EXPERIMENTAL
Intervention: rEpo administration (30 IU/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rEpo administration (various treatments)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multiparametric formula including hematocrit value, reticulocyte count, soluble transferrin receptor content, and beta-globin mRNA concentration
Number of subjects: 18
Study: 9743816

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 1200 mg/day
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 3 x 400 mg/day
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Overall efficacy assessments (physician's and patient's)
Number of subjects: 127
Study: 7999489

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mivacurium 0.15 mg kg‐1
Number of subjects: 96
Study: 3382159

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g I.V. as a single injection performed 1 hour before ESWL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30789580

Group type: EXPERIMENTAL
Intervention: Compression Stockings (20-30 mm Hg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (non-CS)
Number of subjects: 20
Study: 29911435

Group type: EXPERIMENTAL
Intervention: Interdisciplinary committee recommendations for MAOEs
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) therapy recommendations
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Medication administration record (MAR) recommendations
Number of subjects: 145
Study: 28913543

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 0
Study: 28436359

Group type: COMPARATOR
Intervention: Brachytherapy (BT)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 165
Study: 26356808

Group type: EXPERIMENTAL
Intervention: PROSPER delivery system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 28
Study: 24046412

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis spores
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: polyinosinic‐polycytidylic acid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CpG oligodeoxynucleotides (CpG-ODN)
Number of subjects: 10
Study: 22081189

Group type: EXPERIMENTAL
Intervention: Granisetron (1mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ondansetron (4mg)
Number of subjects: 60
Study: 18652326

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Jingming (BL 1), Taiyang (EX‐HN 5), Chengqi (ST 1), Hegu (LI4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Eye drug treatment with local dropping of Aiweiduo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Eye drug treatment
Number of subjects: 80
Study: 16409197

Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SIT) with house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) at maintenance doses of 20, 2,000, and 20,000 SQ‐U weekly for 1 year.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SIT) with house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) at higher doses (2,000 and 20,000 SQ‐U).
Number of subjects: 89
Study: 15199077

Group type: EXPERIMENTAL
Intervention: DRF-1042 at 120 mg/m(2)/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: DRF-1042 at 1.5 to 270 mg/m(2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: DRF-1042
Number of subjects: 25
Study: 11336165

Group type: EXPERIMENTAL
Intervention: Serum sICAM‐1 concentration in colorectal cancer patients
Number of subjects: 94

Group type: COMPARATOR
Intervention: Tissue sICAM‐1 concentration in normal mucosa
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Tissue sICAM‐1 concentration in advanced carcinoma
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ICAM‐1 immunoreactivity in tumor
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Serum sICAM‐1 level
Number of subjects: 94
Study: 9391857

Group type: EXPERIMENTAL
Intervention: Doppler color flow imaging technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional left ventricular outflow method
Number of subjects: 30
Study: 7930386

Group type: EXPERIMENTAL
Intervention: Clomipramine 50 mg orally 2 hours before blood collection
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13
Study: 3286384

Group type: EXPERIMENTAL
Intervention: famotidine 10 mg bolus injection iv followed by continuous infusions of 3.2 mg/h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: famotidine 10 mg bolus injection iv followed by continuous infusions of 4 mg/h
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 28485994

Group type: EXPERIMENTAL
Intervention: Irrigation and suction (IS)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Suction only (SO)
Number of subjects: 260
Study: 26970723

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks
Number of subjects: 287

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 287

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 287
Study: 24372888

Group type: EXPERIMENTAL
Intervention: Metronome‐paced speech condition
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 13
Study: 23598083

Group type: EXPERIMENTAL
Intervention: Task-related training (TRT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standardized outcome measures
Number of subjects: 21
Study: 20949847

Group type: EXPERIMENTAL
Intervention: WCG3 (waist circumference >= 90 cm)
Number of subjects: 84

Group type: COMPARATOR
Intervention: WCG1 (waist circumference < 70 cm)
Number of subjects: 84

Group type: COMPARATOR
Intervention: WCG2 (waist circumference between 70 and 89 cm)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BMI and SFAB
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 84
Study: 19140646

Group type: EXPERIMENTAL
Intervention: Working memory training (twice weekly for 3 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 80
Study: 16766587

Group type: EXPERIMENTAL
Intervention: TAC with primary prophylactic G-CSF (PPG)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: TAC without PPG
Number of subjects: 1047

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: TAC with PPG
Number of subjects: 1047
Study: 12559639

Group type: EXPERIMENTAL
Intervention: Composite outcome (death plus disease occurrence or recurrence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mortality outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method 1 (Bonferroni method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method 2 (joint distribution of test statistics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study: 10404768

Group type: EXPERIMENTAL
Intervention: FV:R506Q mutation (prevalence 2.5%)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Oral contraceptives or hormone replacement therapy
Number of subjects: 955

Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 955

Group type: COMPARATOR
Intervention: Smoking markers
Number of subjects: 955

Group type: COMPARATOR
Intervention: Age
Number of subjects: 955

Group type: COMPARATOR
Intervention: Gender (Women vs Men)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Total cholesterol and diastolic blood pressure
Number of subjects: 955

Group type: COMPARATOR
Intervention: Triglycerides, systolic blood pressure, and body mass index (in women)
Number of subjects: 955
Study: 7861317

Group type: EXPERIMENTAL
Intervention: Latinos distinguishing between their own subgroup and others
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Perception of the term Hispanic
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Subgroup differentiation based on positive distinctiveness
Number of subjects: 3
Study: 2672868

Group type: EXPERIMENTAL
Intervention: Epidural ketamine (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural diamorphine (5 mg)
Number of subjects: 20
Study: 333601

Group type: EXPERIMENTAL
Intervention: Parenteral cefazolin begun before operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic present in the tissues at the time of inoculation or resistant bacteria
Number of subjects: 0
Study: 30293666

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1606
Study: 28720980

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Therapy (CRT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study: 26200164

Group type: EXPERIMENTAL
Intervention: Xenograft with equine origin (Apatos, Osteobiol; Tecnoss Dental)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Xenograft (1 g) + porous titanium (1 g) granules (Natix; Tigran Technologies AB)
Number of subjects: 8
Study: 24599947

Group type: EXPERIMENTAL
Intervention: Mindful attention manipulation
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: State mindfulness
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study: 21987227

Group type: EXPERIMENTAL
Intervention: Modular cognitive behavioral therapy (CBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 3‐month waitlist
Number of subjects: 24
Study: 20151520

Group type: EXPERIMENTAL
Intervention: Obturator and femoral cutaneous nerve blocks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Total intravenous analgesia
Number of subjects: 75
Study: 17164979

Group type: EXPERIMENTAL
Intervention: High flavanol cocoa (329 mg flavanols, 61 mg epicatechin per 100 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low flavanol cocoa (27 mg flavanols, 6.6 mg epicatechin per 100 ml)
Number of subjects: 10
Study: 15078803

Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 1314
Study: 12006189

Group type: EXPERIMENTAL
Intervention: Long pulse flashlamp pumped pulsed dye laser (LPDL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cryogen coolant only
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LPDL
Number of subjects: 15
Study: 9835727

Group type: EXPERIMENTAL
Intervention: SP Group (single shot spinal anesthesia)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PD Group (continuous epidural anesthesia)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 8008484

Group type: EXPERIMENTAL
Intervention: Stimulable phosphor technology
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional screen-film technology
Number of subjects: 100
Study: 3627579

Group type: EXPERIMENTAL
Intervention: Labetalol plus hospitalization
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hospitalization alone
Number of subjects: 200
Study: 31919539

Group type: EXPERIMENTAL
Intervention: Supportive text messages using mobile phone SMS messages 2-3 times per week
Number of subjects: 2062

Group type: COMPARATOR
Intervention: Standard advice on a healthy lifestyle
Number of subjects: 2062
Study: 29674362

Group type: EXPERIMENTAL
Intervention: Implementation of the ACI model of care for acute low back pain, including educational materials and seminars, and an audit and feedback approach.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Not applicable (control period).
Number of subjects: 200
Study: 26378118

Group type: EXPERIMENTAL
Intervention: MCT/ω-3 PUFA-enriched IVFE
Number of subjects: 60

Group type: COMPARATOR
Intervention: Soybean oil-based IVFE
Number of subjects: 60
Study: 23574694

Group type: EXPERIMENTAL
Intervention: Scale for Health-Promoting Schools (SHPS)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: School nutrition services (3-item, α = 0.87)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Healthy school policies (6-item, α = 0.87)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: School's physical environment (10-item, α = 0.91)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: School's social environment (4-item, α = 0.88)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Community links (6-item, α = 0.91)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Individual health skills and action competencies (3-item, α = 0.89)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Health services (5-item, α = 0.86)
Number of subjects: 728
Study: 22317387

Group type: EXPERIMENTAL
Intervention: Improved land preparation tools (clod breaker, improved plough/'danella')
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Traditional tools
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Improved land preparation tools
Number of subjects: 1800
Study: 20456814

Group type: EXPERIMENTAL
Intervention: Whey protein meal
Number of subjects: 22
Study: 17805486

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Vinorelbine (GV)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Docetaxel (GD)
Number of subjects: 39
Study: 19172341

Group type: EXPERIMENTAL
Intervention: Ribonuclease-enriched lactoferrin (R-ELF) supplement
Number of subjects: 38
Study: 16360958

Group type: EXPERIMENTAL
Intervention: Extended-release metoprolol succinate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 100